Edgewise Therapeutics (EWTX)
(Real Time Quote from BATS)
$22.66 USD
-0.21 (-0.92%)
Updated Jul 16, 2024 01:44 PM ET
2-Buy of 5 2
D Value F Growth B Momentum D VGM
Price, Consensus and EPS Surprise
EWTX 22.66 -0.21(-0.92%)
Will EWTX be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for EWTX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for EWTX
Wall Street Analysts Predict a 52.78% Upside in Edgewise Therapeutics, Inc. (EWTX): Here's What You Should Know
Wall Street Analysts See a 33.27% Upside in Edgewise Therapeutics, Inc. (EWTX): Can the Stock Really Move This High?
EWTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Wall Street Analysts Think Edgewise Therapeutics, Inc. (EWTX) Could Surge 70.76%: Read This Before Placing a Bet
Edgewise (EWTX) Rallies 35% on Issue of New Common Stock
Wall Street Analysts See a 310.1% Upside in Edgewise Therapeutics, Inc. (EWTX): Can the Stock Really Move This High?
Other News for EWTX
Edgewise Therapeutics added to Best Ideas List at Wedbush
Edgewise Therapeutics management to meet with Piper Sandler
Edgewise Therapeutics management to meet with Piper Sandler
Truist Financial Reaffirms Their Buy Rating on Edgewise Therapeutics (EWTX)
Edgewise Therapeutics participates in a conference call with JPMorgan